Welcome to STN International! Enter x:x

LOGINID:ssspta1200exs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS 2 | Apr 08 | "Ask CAS" for self-help around the clock |
| NEWS 3 | Apr 09 | BEILSTEIN: Reload and Implementation of a New Subject Area |
| NEWS 4 | Apr 09 | ZDB will be removed from STN |
| NEWS 5 | Apr 19 | US Patent Applications available in IFICDB, IFIPAT, and IFIUDB |
| NEWS 6 | Apr 22 | Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS |
| NEWS 7 | Apr 22 | BIOSIS Gene Names now available in TOXCENTER |
| NEWS 8 | Apr 22 | Federal Research in Progress (FEDRIP) now available |
| NEWS 9 | Jun 03 | New e-mail delivery for search results now available |
| NEWS 10 | Jun 10 | MEDLINE Reload |
| NEWS 11 | Jun 10 | PCTFULL has been reloaded |
| NEWS 12 | Jul 02 | FOREGE no longer contains STANDARDS file segment |
| NEWS 13 | Jul 22 | USAN to be reloaded July 28, 2002; saved answer sets no longer valid |
| NEWS 14 | Jul 29 | Enhanced polymer searching in REGISTRY |
| NEWS 15 | Jul 30 | NETFIRST to be removed from STN |
| NEWS 16 | Aug 08 | CANCERLIT reload |
| NEWS 17 | Aug 08 | PHARMAMarketLetter(PHARMAML) - new on STN |
| NEWS 18 | Aug 08 | NTIS has been reloaded and enhanced |
| NEWS 19 | Aug 19 | Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN |
| NEWS 20 | Aug 19 | IFIPAT, IFICDB, and IFIUDB have been reloaded |
| NEWS 21 | Aug 19 | The MEDLINE file segment of TOXCENTER has been reloaded |
| NEWS 22 | Aug 26 | Sequence searching in REGISTRY enhanced |
| NEWS 23 | Sep 03 | JAPIO has been reloaded and enhanced |
| NEWS 24 | Sep 16 | Experimental properties added to the REGISTRY file |
| NEWS 25 | Sep 16 | CA Section Thesaurus available in CAPLUS and CA |
| NEWS 26 | Oct 01 | CASREACT Enriched with Reactions from 1907 to 1985 |
| NEWS 27 | Oct 21 | EVENTLINE has been reloaded |
| NEWS 28 | Oct 24 | BEILSTEIN adds new search fields |
| NEWS 29 | Oct 24 | Nutraceuticals International (NUTRACEUT) now available on STN |
| NEWS 30 | Oct 25 | MEDLINE SDI run of October 8, 2002 |
| NEWS 31 | Nov 18 | DKILIT has been renamed APOLLIT |
| NEWS 32 | Nov 25 | More calculated properties added to REGISTRY |
| NEWS 33 | Dec 02 | TIBKAT will be removed from STN |
| NEWS 34 | Dec 04 | CSA files on STN |
| NEWS 35 | Dec 17 | PCTFULL now covers WP/PCT Applications from 1978 to date |
| NEWS 36 | Dec 17 | TOXCENTER enhanced with additional content |
| NEWS 37 | Dec 17 | Adis Clinical Trials Insight now available on STN |
| NEWS 38 | Dec 30 | ISMEC no longer available |

NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003
NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 43 Feb 13 CANCERLIT is no longer being updated
NEWS 44 Feb 24 METADEX enhancements
NEWS 45 Feb 24 PCTGEN now available on STN
NEWS 46 Feb 24 TEMA now available on STN
NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 48 Feb 26 PCTFULL now contains images
NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:11:11 ON 13 MAR 2003

=> file caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'CAPLUS' ENTERED AT 10:11:23 ON 13 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Mar 2003 VOL 138 ISS 11
FILE LAST UPDATED: 12 Mar 2003 (20030312/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 1,3-cyclic glycerophosphate
       7465882 1
       5712254 3
        258238 CYCLIC
          8095 GLYCEROPHOSPHATE
L1           2 1,3-CYCLIC GLYCEROPHOSPHATE
                 (1(W)3(W)CYCLIC(W)GLYCEROPHOSPHATE)

=> d l1 1-2 all

L1   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS
AN   2000:706969  CAPLUS
DN   133:261536
TI   Pharmaceutical compositions comprising cyclic glycerophosphates and
     analogs thereof for promoting neural cell differentiation
IN   Shinitzky, Meir
PA   Yeda Research and Development Co. Ltd., Israel
SO   PCT Int. Appl., 42 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM  A61K031-00
CC   1-11 (Pharmacology)
     Section cross-reference(s): 29, 63
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.   DATE
     ---------------   ----  --------       ---------------   --------
PI   WO 2000057865      A2   20001005       WO 2000-IL185     20000324
     WO 2000057865      A3   20010628
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
             LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
             SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
             ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     BR 2000009296      A    20011218       BR 2000-9296      20000324
     EP 1162959         A2   20011219       EP 2000-912877    20000324
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2002540146      T2   20021126       JP 2000-607616    20000324
PRAI IL 1999-129178     A    19990325
     WO 2000-IL185      W    20000324
OS   MARPAT 133:261536
```

AB Cyclic glycerophosphates and analogs thereof (CGs) are shown to exert neural promoting activities in target cells. Such activities include promotion of neuronal outgrowth, promotion of nerve growth, provision of dopaminotrophic supporting environment in a diseased portion of the brain, prevention of nerve degeneration and nerve rescue. These activities of the CGs render them useful for treatment of various disorders including but not limited to mental disorders such as, for example, schizophrenia, dementia or disorders resulting in learning disabilities. In addn., these CGs may be used for the treatment of neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, conditions resulting from exposure to harmful environmental factors or resulting from a mech. injury. The CGs may also be used to treat an individual suffering from a primary neurodegenerative condition in order to prevent or reduce the appearance of secondary degeneration in addnl. nerves ("nerve rescue"). For example, neural outgrowth of PC12 cells was seen when cells were grown in the presence of nerve growth factor (50 ng/mL) or **1,3-cyclic glycerophosphate** (1 .mu.M), but not in the presence of linear .alpha.-glycerophosphate.

ST cyclic glycerophosphate neuronal differentiation mental disorder; antipsychotic schizophrenia cyclic glycerophosphate; Alzheimer disease parkinsonism cyclic glycerophosphate

IT Anti-Alzheimer's agents
Antiparkinsonian agents
Antipsychotics
Mental disorder
Nervous system agents
Schizophrenia
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Monoamines
Neurotrophic factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Nerve
(degeneration, prevention of; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Mental disorder
(dementia; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Nerve
(differentiation; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Learning
(disorder; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Nerve
(dopaminergic, degeneration of; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

IT Cell differentiation

(inducers; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT Nerve, disease
(injury, neuronal rescue after; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT Cell differentiation
Cell differentiation
(neuronal; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT Drug delivery systems
(oral; compns. comprising cyclic glycerophosphates for promoting neural
differentiation for therapeutic uses)
IT Drug delivery systems
(osmotic pumps; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT Cell proliferation
(promotion of; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT Drug delivery systems
(topical; compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT 298701-05-0P
RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT 711-07-9P 13507-10-3P 22227-09-4P 118897-32-8P 123406-35-9P 286020-33-5P 298701-06-1P 298701-08-3P 298701-09-4P 298701-78-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT 51-61-6, Dopamine, biological studies 59-92-7, biological studies 102-32-9, DOPAC 306-08-1, Homovanillic acid
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT 9001-86-9, Phospholipase C
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)
IT 57-55-6, 1,2-Propanediol, reactions 96-26-4, Dihydroxyacetone 504-63-2, 1,3-Propanediol 770-12-7, Phenyl phosphorodichloridate 819-83-0, Disodium .beta.-glycerophosphate 4799-67-1 14690-00-7, 2-Benzyloxy-1,3-propanediol 22002-87-5 26776-70-5, Dihydroxyacetone dimer
RL: RCT (Reactant); RACT (Reactant or reagent)
(compns. comprising cyclic glycerophosphates for promoting neural

differentiation for therapeutic uses)
IT 187976-16-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(compns. comprising cyclic glycerophosphates for promoting neural differentiation for therapeutic uses)

L1 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 1993:534139 CAPLUS
DN 119:134139
TI Formation of **1,3-cyclic glycerophosphate** by the action of phospholipase C on phosphatidylglycerol
AU Shinitzky, Meir; Friedman, Peter; Haimovitz, Rachel
CS Dep. Membrane Res. Biophys., Weizmann Inst. Sci, Rehovot, 76100, Israel
SO Journal of Biological Chemistry (1993), 268(19), 14109-15
CODEN: JBCHA3; ISSN: 0021-9258
DT Journal
LA English
CC 7-3 (Enzymes)
AB The action of phospholipase C (PLC) from Bacillus cereus on phosphatidylglycerol (PG), derived from egg yolk phosphatidylcholine (PC), was examd. in an ether-water mixt. The PLC cleavage of PG and PC followed a Michaelis-Menten kinetics with apparent Vmax values per 1 .mu.g enzyme of 0.26 and 0.91 .mu.mol.min-1 and Km values of 10 and 12 mM, resp. When the same enzymic reaction was carried out in minimally buffered aq. soln. of 1% Triton X-100, the decrease in pH with respect to phospholipid cleavage was as expected with PC but much less pronounced with PG. This could be accounted for by .alpha.-glycerophosphate, in the PLC hydrolysis of PG. Examn. of the chem. nature of the water-sol. product of PG by 31P NMR revealed a single band at 2.31 ppm, while the bands of .alpha.-glycerophosphate and .beta.-glycerophosphate appeared at 5.12 and 4.57 ppm, resp. Basic hydrolysis of the phospholipase cleavage product of PG (0.1 M NaOH for 1 min at 80 .degree.C) followed by neutralization shifted its 31P NMR band to 5.18 ppm, which practically coincided with that of .alpha.-glycerophosphate. Analogous expts. were carried out with PG labeled with 3H at the carbon 2 of the glycerol headgroup ([3H]PG). Autoradiog. of thin layer chromatog. (TLC) of the [3H]PG enzymic hydrolyzate displayed a single 3H-labeled compd., which could be converted to .alpha.-glycerophosphate by basic hydrolysis. These results strongly suggest that the phosphate headgroup of PG is cleaved off by PLC as **1,3-cyclic glycerophosphate**. A series of PLC expts. with phosphatidyldihydroxyacetone and phosphatidyl 1,3-propanediol as model substrates supported this assignment. Two-dimensional homonuclear 1H NMR correlated spectra as well as IR spectra carried out on the isolated sodium salt of this product could further confirm such a structure. The unique structure and chem. nature of **1,3-cyclic glycerophosphate** may bear a distinct physiol. function.
ST cyclic glycerophosphate formation phospholipase C phosphatidylglycerol
IT Phosphatidylglycerols
RL: RCT (Reactant); RACT (Reactant or reagent)

(cleavage of, by phospholipase C, cyclic glycerophosphate formation in)
IT Michaelis constant
(of phospholipase C, with phosphatidylglycerol)
IT Phosphatidylcholines, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with phospholipase C, kinetics of, phosphatidylglycerol in relation to)
IT 9001-86-9, Phospholipase C
RL: BIOL (Biological study)
(cyclic glycerophosphate formation by, of Bacillus cereus, in phosphatidylglycerol cleavage)
IT 42320-97-8
RL: FORM (Formation, nonpreparative)
(formation of, by phospholipase C cleavage of phosphatidylglycerol)
IT 149864-37-9
RL: FORM (Formation, nonpreparative)
(formation of, by phospholipase C cleavage of phosphatidylhydroxyacetone)
IT 13507-10-3
RL: FORM (Formation, nonpreparative)
(formation of, by phospholipase C cleavage of phosphatidylpropanediol)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 13.58 | 13.79 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -1.30 | -1.30 |

STN INTERNATIONAL LOGOFF AT 10:13:20 ON 13 MAR 2003